ERBB2 and breast carcinoma: mTNBC accounts for approximately 15–20% of all breast cancers and is characterised by aggressive behaviour with high invasiveness, leading to elevated relapse rates, high mortality, poor prognosis, and limited targeted treatment options owing to the lack of PR, ER, and HER2 expression [3,4,5].